HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

sepiapterin

structure
Also Known As:
2-amino-6-(S)-lactoyl-7,8-dihydro-4(3H)- pteridinone; sepia-pterin
Networked: 37 relevant articles (5 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Shi, Yang: 4 articles (01/2013 - 03/2010)
2. Vásquez-Vivar, Jeannette: 3 articles (02/2014 - 10/2002)
3. Warltier, David C: 3 articles (01/2013 - 03/2010)
4. Kersten, Judy R: 3 articles (01/2013 - 03/2010)
5. Otani, Hajime: 2 articles (11/2015 - 11/2011)
6. Shimazu, Takayuki: 2 articles (11/2015 - 11/2011)
7. Yoshioka, Kei: 2 articles (11/2015 - 11/2011)
8. Iwasaka, Toshiji: 2 articles (11/2015 - 11/2011)
9. Fujita, Masanori: 2 articles (11/2015 - 11/2011)
10. Alam, Asim: 2 articles (06/2015 - 10/2013)

Related Diseases

1. Anoxia (Hypoxia)
08/01/2011 - "In conclusion, the administration of sepiapterin can prevent renal hypoxia and AKI after suprarenal aortic clamping in rats."
09/01/2009 - "Sepiapterin treatment also reduced incidence of severe motor deficits and perinatal death following E22 hypoxia-ischemia. "
09/01/2009 - "Maternal supplementation prior to hypoxia-ischemia with sepiapterin increased BH(4) in all brain regions and especially in the thalamus, but did not increase the intermediary metabolite, 7,8-BH(2). "
01/01/2013 - "Thus, even though eNOS gene deletion and sepiapterin treatment exert protective effects on hypoxia-induced pulmonary vascular remodelling, increase on right ventricular pressure and / or right ventricular hypertrophy, these effects appear unrelated to biopterin-dependent eNOS uncoupling within pulmonary vasculature of hypoxic wild-type mice. "
01/01/2013 - "This EC-derived protection was abolished by HG. The addition of 100 µM sepiapterin (a BH4 precursor) or overexpression of GTP cyclohydrolase 1 (the rate-limiting enzyme for BH4 biosynthesis) in ECs by gene trasfer enhanced endothelial BH4 levels, the ratio of eNOS dimer/monomer, eNOS phosphorylation, and NO production and decreased lactate dehydrogenase activity in the presence of HG. These results demonstrate that increased BH4 content in ECs by either pharmacological or genetic approaches reduces myocardial damage during hypoxia/reoxygenation in the presence of HG. Maintaining sufficient endothelial BH4 is crucial for cardioprotection against hypoxia/reoxygenation injury. "
2. Atherosclerosis
3. Ischemia
4. Myocardial Stunning (Stunned Myocardium)
5. Right Ventricular Hypertrophy

Related Drugs and Biologics

1. Biopterin
2. Azoxymethane
3. 5,6,7,8-tetrahydrobiopterin (tetrahydrobiopterin)
4. Arginine (L-Arginine)
5. Dexamethasone (Maxidex)
6. Desoxycorticosterone (DOCA)
7. Bleomycin (Blenoxane)
8. Adrenocorticotropic Hormone (ACTH)
9. Acetylcysteine (Siran)
10. Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)

Related Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Oral Administration